Abstract
INTRODUCTION
The left atrial appendage (LAA) is considered to be the dominant source of embolism (> 90%) in patients with non-valvular atrial fibrillation (AF) [1] . Occlusion or resection of the left atrial appendage occlusion (LAAO) remains an important intervention for prevention of recurrent emboli in patients who are at risk of stroke. LAAO provides an opportunity to avoid systemic anti coagulation, thereby minimizing the risk of bleeding.
Surgical LAAO (sLAAO) usually involves LAA closure while performing other cardiac surgeries. With the increasing prevalence of AF [2] , there is a growing interest in the surgical community for sLAAO. Prior studies assessing the clinical impact of surgical occlusion of the LAA during cardiac surgery have shown contradictory results [314] . Furthermore, there are no large scale randomized controlled trials evaluating routine sLAAO during cardiac surgery. Therefore sLAAO remains a class IIb recommendation in professional medical society guidelines [15, 16] . Despite this recommendation, sLAAO is routinely performed in patients with AF undergoing cardiac surgery. Therefore, we sought to perform a metaanalysis of the available studies published to date to evaluate the safety and efficacy of concomitant s-LAAO vs no occlusion during cardiac surgery [3, 4, 614] .
MATERIALS AND METHODS

Search strategy
The systematic review and metaanalysis was done in compliance with PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalysis) guidelines [17] . The PRISMA checklist is presented in Supplementary Table 1 . The initial search strategy was developed by two authors (V.A and M.A.N). We performed a systematic search, without language restriction, using PubMed, EMBASE, SCOPUS, Google Scholar, and ClinicalTrials.gov from inception to May 31st, 2018 for studies comparing sLAAO vs no occlusion only in patients undergoing concomitant cardiac surgery. We used the following keywords and medical subject heading: "Cardiac surgeries" OR "Heart surgeries" OR "Cardiac surgical procedures" AND "Left atrial appendage" OR "occlusion" OR "ligation" OR "resection" OR "excision" OR "amputation".
Study selection and data extraction
Only studies comparing sLAAO vs no occlusion during any cardiac surgery were included in our analysis. The reference lists of original studies, conference abstracts and relevant review articles were further reviewed. Two investigators (V.A and M.A.N) independently per formed the literature search, reviewed the originally identified titles and abstracts and selected studies for pooled analysis based on the inclusion criteria. Any divergence was resolved through discussion with a third independent reviewer (M.K.T). The quality of observational studies was assessed using the Newcastle Ottawa scale, Supplementary Table 2 .
Clinical outcomes
We evaluated the following clinical outcomes during followup in each report: (1) embolic events; (2) stroke; (3) all-cause mortality; (4) AF; (5) postoperative complications; and (6) reoperation for bleeding. We further performed stratified metaanalysis to evaluate the potential source of heterogeneity across the in cluded studies. Stratification factors are inclusion of only propensity matched studies and studies with AF predominant cohort (> 50% of study population having AF). The ischemic events attributed to embolic causes in the included studies were included in the embolic events.
Complications included in the analysis are appendage tears, myocardial infarction, major bleeding, septicemia, pacemaker implants, renal failure, pericardial effusion, cardiac tamponade, and stroke.
Statistical analysis
The metaanalysis was done using Review Manager (RevMan), Version 5.3. Copenhagen: The Nordic Co chrane Centre, the Cochrane Collaboration, 2014. Due to methodological and clinical heterogeneity between the included studies, a randomeffects model estimating the odds ratio (OR) and the estimated 95% confidence interval (CI) of the abovementioned outcomes were used. The OR estimate of each study was calculated by the randomeffects model obtained by the DerSimonian Lariad method [18] . Heterogeneity was assessed using Higgins' and Thompson's I2 statistic, with I2 values of > 50% was considered significant. Publication bias was visually estimated by funnel plots. A 2tailed P < 0.05 was con sidered statistically significant for all analyses.
RESULTS
Search results
A total of 1328 reports were retrieved during the initial search (Supplementary figure 1) . 1049 reports were selected after removing 279 duplicates. 387 reports were screened and 354 were excluded. 33 reports were assessed for eligibility. Finally, after excluding 21 reports (no comparison groups14, others7) 12 studies were included. Among these 12 studies, three were randomized controlled trials (RCTs) and nine were obser vational studies. Among these nine observational studies, four were propensity matching studies [5, 6, 10, 13] . one was case matching study [12] . The interreviewer agreement on study eligibility was 100%.
Study characteristics
The characteristics of the included studies are presented in Table 1 and Table 2 . Out of 40107 patients included, 13535 patients received sLAAO during cardiac surgery while the remaining 26572 patients did not receive sLAAO. The mean (SD) age of the study population ranged from 50.7 (12.4) years to 77.4 (6.8) years. The primary cardiac operation varied widely. The surgical procedures were primarily valve surgery in the studies by Garcia-Fernandez, Nagpal, Lee and Elbadawi [3, 5, 8, 12] , while they were primarily coronary artery bypass grafting (CABG) in the studies by Healey, and Elbadawi [7, 11] .
Remaining studies included a combination of valve sur gery and CABG. Lee et al [5] also performed ablation of AF together with mitral valve surgery. The prevalence of AF varied in the study cohorts. The s-LAAO techniques varied; the methods variously included double suturing, exclusion, amputation, resection and stapling ( Table 2 ). The followup period ranged from inhospital only to 109.2 mo.
Clinical outcomes
sLAAO was associated with lower risk of embolic events (OR: 0.63, 95%CI: 0.530.76; P < 0.001) and a lower risk of stroke (OR: 0.68, 95%CI: 0.570.82; P < 0.0001) ( Figure 1A and 1B). There was no significant difference in allcause mortality between the two groups (OR: 0.83, 95%CI: 0.511.36; P = 0.46) ( Figure 1C ). There was no significant difference in the incidence of follow-up AF between the two groups (OR: 1.41, 95%CI: 0.792.52, P = 0.24) ( Figure 1D ). With regard to postoperative complications, there was no significant difference between the groups (OR: 1.44, 95%CI: 0.912.25; P = 0.12) ( Figure 1F ). Similarly, there was no significant difference in the incidence of reoperation for bleeding between the two groups (OR: 0.98, 95%CI: 0.571.69; P = 0.94) ( Figure  1G ).
Test of heterogeneity and publication bias
Test of heterogeneity was not significant for follow-up embolic events (P heterogeneity = 0.60, I2 = 0%) and stroke (P = 0.84, I2 = 0%), while it was significant for allcause mortality (P < 0.001, I2 = 92%), AF (P < 0.001, I2 = 95%), postoperative complications (P = 0.004, I2 = 66%) and reoperation for bleeding (P = 0.20, I2 = 36%).
Subgroup analysis
In subgroup analysis including only propensity matched studies, sLAAO group had a trend towards lower risk of stroke (OR: 0.78, 95%CI: 0.601.00; P = 0.05), Supplementary Figure 2A . Test of heterogeneity was not significant (P = 0.63, I2 = 0%). There was no significant difference in the incidence of allcause mortality (OR: 1.10, 95%CI: 0.343.60; P = 0.87), Supplementary Figure 2B . In subgroup analysis including only AF predominant studies (> 50%), sLAAO was associated with lower risk of stroke (OR: 0.60, 95%CI: 0.460.78; P = 0.0002) (Supplementary Figure 3A) . There was no significant difference in allcause mortality (OR: 0.87, 95%CI: 0.117.12; P = 0.89) (Supplementary Figure  3B) . Test of heterogeneity was not significant for stroke (P = 0.86, I2 = 0%) while it was significant for all-cause mortality (P < 0.001, I2 = 94%).
Funnel plot for visual inspection of publication bias is shown in Supplementary Figure 4 .
DISCUSSION
The main findings of our meta-analysis of patients unAtti V et al . SLAAO during cardiac surgery compliance and cost [16] . The higher risk of stroke in the ageing population with AF has led to the increased adoption of LAA occlusion in clinical practice [23] . The two largest RCTs -PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) and PREVAIL (Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) showed percutaneous LAAO being noninferior to warfarin with respect to stroke rates and embolic events [24, 25] . Following the success with percutaneous LAAO, there has been a resurgence of interest in sLAAO within the surgical community, especially with increase in the aging population and rising prevalence of AF [6, 10, 14] . Our findings show that s-LAAO was associated with lower risk of followup embolic events and stroke. The association of lower risk of stroke was more prominent in subgroup with AF predominant population. S-LAAO theoretically prevents formation of thrombus in LAA. However, successful sLAAO is largely influenced by LAA morphology, occlusion technique and also operator dergoing sLAAO during concomitant cardiac surgery are the following: (1) sLAAO was associated with lower rates of embolic events and stroke; and (2) there was no significant difference in the incidence of allcause mortality, postoperative complications or reoperations for bleeding between the two groups. The reduced risk of embolic events and stroke with sLAAO was retained in the subgroup analysis including only studies with AF predominant population ( Table 3) .
The estimated global prevalence of AF is on the rise due to a demographic shift with more prevalent ageing population carrying a higher burden of comorbidities [19] . About 25% of the strokes in the United States are related to AF and about 90% of the strokes in nonvalvular AF are caused by thrombi originating in LAA [20] . Anticoagulants, both warfarin and direct acting oral anticoagulants (DOACs) reduce the incidence of stroke by more than 60% [21, 22] but they are associated with increasing risk of bleeding, and significant drugdrug interactions [16] . The benefits of anticoagulants are also limited by other issues including underutilization, poor [12] 71.3 ± 9 70.6 ± 8.7 78.5 76.1 100 100 NR Friedman et al, 2018 [14] 75 ± 5.9
76. tears as observed in the study by Healey et al [7] and so learning curve plays an essential role in success of the procedure. Hypothetically, avoidance of aggressive anticoagulation after sLAAO might have contributed to some of the benefits observed with sLAAO. However, only few studies reported the longterm details of anticoagulation. Lee et al [5] reported no difference in the utilization of anticoagulation between the two groups (62.2% vs 55.4%). In the study by Friedman et al [14] , anticoagulation was prescribed to 68.9% of the patients in the sLAAO group compared to only 60.3% in the group without sLAAO. In contrast to percutaneous LAAO, evidence regarding the utilization of anticoagulation after sLAAO is not clear. The 2016 ESC/EACTS guidelines still recommend therapeutic anticoagulation in all patients despite sLAAO (Class Ⅰ, level of evidence B) [15] . With lack of long term data, there is need for prospective trials to address this issue. The ongoing LAAOSⅢ (left atrial appendage occlusion study Ⅲ) and the ATLAS (AtriClip ® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures) trials should be able to provide further insights into the benefits of s-LAAO.
LIMITATIONS
Our study should be viewed in the context of following limitations. First, due to the small number of studies with small sample sizes, except the study by Friedman et al [14] , the results might be underpowered to detect the true clinical benefits of certain clinical outcomes. Second, there was a wide variation of surgical tech niques of LAAO, so we were not able to address the effect of individual techniques. Third, only Friedman et skill. A previous study showed that a complete LAA occlusion was achieved in only 40%50% of the patient population [10, 26] . The techniques of sLAAO varied widely amongst the included studies as summarized in Table  2 . The excision technique to exclude LAA has been shown to have a higher success rate than the other modalities of sLAAO [24] . Currently, concomitant LAA closure is given a Class Ⅱb (level of evidence B) by the European Society of Cardiology (ESC)/European Society for CardioThoracic Surgery (EACTS) guidelines and a Class IIb (level of evidence C) by the 2017 Society of Thoracic Surgeons guidelines (STS) [16] . Therefore, there is a wide practice level variation in the utiliza tion of sLAAO during cardiac surgery. The number of studies with a particular technique is inadequate to perform individual technique based metaanalysis so we combined all different techniques of sLAAO in our metaanalysis. It should be noted that none of the other studies except the study from Friedman et al [14] reported long-term benefits. However, Friedman et al [14] showed a remarkable reduction in postoperative embolism at follow up. Further studies with long-term follow up of embolic events are essential. Our results are similar to a previous metaanalysis comparing sLAAO vs no occlusion [27, 28] . However, we included additional studies by Friedman et al [14] , Elbadawi et al [11] and Yao et al [13] yielding a larger sample size. In addition, we performed a subgroup analysis of the included studies to identify the patient population that is most likely to benefit from this procedure.
In the current study, we found no significant dif ference in the risk of postoperative complications and reoperation for bleeding. sLAAO is associated with inherent risk of procedural complications including LAA [8] al [14] reported longterm embolic events, whereas the other studies did not report long term outcomes. The study by Friedman et al [14] reported readmissions for embolic events, so some of the events which did not require hospitalization were not included. The effect of anticoagulation on postoperative outcomes remains unclear due to inadequate reporting in the included studies. Fourth, it is unclear if s-LAAO increases the duration of the surgical procedure as it was only reported in two studies. Fifth, the burden of AF varied among the included studies, thus carrying risk of a selection bias. Finally, publication bias is an inherent limitation of any metaanalysis.
CONCLUSION
In conclusion, our results support the safety of sLAAO and favor its continued use in conjunction with conco mitant cardiac surgery, especially in patients with AF. Randomized controlled trials are essential to evaluate the long-term benefits of s-LAAO.
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Research background
The left atrial appendage (LAA) is a common site for intracardiac thrombus formation in patients with atrial fibrillation (AF). Surgical left atrial appendage occlusion (s-LAAO) during concomitant cardiac surgery has been evaluated as an effective treatment approach to reduce the risk of stroke and embolic events.
Research motivation
Percutaneous LAAO has been shown to be non-inferior compared with warfarin in reducing the risk of stroke and embolic events in two large randomized controlled trials, PROTECT-AF and PREVAIL. However, data regarding s-LAAO is conflicting and contrasting. So, we performed a systematic review and metaanalysis of all the studies published to date to evaluate if concomitant s-LAAO during cardiac surgery is safe and effective.
Research objectives
The purpose of this study is to evaluate the safety and efficacy of concomitant s-LAAO during cardiac surgery.
Research methods
We searched five databases for studies comparing concomitant s-LAAO with no occlusion during cardiac surgery. We obtained a total of 12 studies for inclusion and performed a meta-analysis. The outcomes of interest were embolic events, stroke, all-cause mortality, AF, postoperative complications and reoperation for bleeding.
Research results
Concomitant s-LAAO during cardiac surgery was associated with lower risk of embolic events and stroke. This was evident in the AF predominant strata as well. There was no significant difference in the risk of all-cause mortality, AF, postoperative complications and reoperation for bleeding.
Research conclusions
Our meta-analysis including all the studies published to date comparing concomitant s-LAAO against no occlusion during cardiac surgery supports the use of concomitant s-LAAO during cardiac surgeries. It was associated with lower risk of stroke and embolic events.
Research perspectives
From this meta-analysis, it could be seen that concomitant s-LAAO during
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